GH Replacement Improves Quality of Life and Metabolic Parameters in Cured Acromegalic Patients with Growth Hormone Deficiency
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Objective Effects of GH replacement in patients with GH deficiency (GHD) after a cure for acromegaly so far have been poorly studied, although its prevalence among acromegalic patients may reach the 60%. The aim of the study was to evaluate whether metabolic parameters and quality of life are improved by GH replacement in patients with prior acromegaly and severe GHD. Design and methods This was a prospective study on 42 GHD subjects [22 men, mean age (sd): 48 ± 10]: 10 acromegalics treated with recombinant human GH (group A), 12 acromegalics who refused treatment (group B), and 20 subjects operated for nonfunctioning pituitary adenoma on recombinant human GH (group C). Serum IGF-I levels, lipid profile, glucose levels (fasting and after an oral glucose tolerance test), glycosylated hemoglobin, insulin resistance (homeostasis model assessment insulin resistance index), anthropometric parameters (body mass index, waist circumference, body composition), and quality of life (Questions on Life Satisfaction-Hypopituitarism Z-scores) were evaluated at baseline and after 12 and 36 months. Results At baseline, group B showed higher IGF sd score than group A and C, as well as better quality of life and higher post-oral glucose tolerance test glucose levels than group A. After 12-months, similarly in group A and C, the IGF-I sd score significantly increased, and body composition and lipid profile improved, without deterioration of glucose tolerance. Quality of life significantly improv…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rates of pituitary axes recovery or new onset hypopituitarism after transsphenoidal surgery vary significantly between studies (115,233,234).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [234]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“The low-density lipoprotein (LDL)-cholesterol levels were calculated by the following formula: LDL-cholesterol [(total cholesterol HDL) TG/5] (21).”
MethodMatthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“Insulin resistance was determined using the homeostasis model assessment (20): homeostasis model assessment insulin resistance index fasting insulin (milliunits per liter) fasting glucose (milligrams per deciliter)/22.”
MethodSalomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
A Consensus on Criteria for Cure of Acromegaly
Giustina, A., Chanson, P., Bronstein, M. D., Klibanski, A., Lamberts, S., Casanueva, F. F., Trainer, P., Ghigo, E., Ho, K., & Melmed, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2670 · Cited by 783 · cited 1×
“Acromegalics were considered cured according to the current guidelines (14).”
BackgroundClinical Aspects of Growth Hormone Deficiency in Adults
BOER, H. D., BLOK, G.-J., & DER VEEN, E. A. V. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-63 · Cited by 723
Clinical aspects of growth hormone deficiency in adults
de Boer, H. (1995) · Endocrine Reviews · doi:10.1210/er.16.1.63 · Cited by 402
Corneli, G., Di Somma, C., Baldelli, R., Rovere, S., Gasco, V., Croce, C. G., Grottoli, S., Maccario, M., Colao, A., Lombardi, G., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01967 · Cited by 317
Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults
Drake, W. M., Coyte, D., Camacho‐Hübner, C., Jivanji, N. M., Kaltsas, G., Wood, D., Trainer, P. J., Grossman, A. B., Besser, G. M., & Monson, J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.3913 · Cited by 236
Predictors of morbidity and mortality in acromegaly: an Italian survey
Arosio, M., Reimondo, G., Malchiodi, E., Berchialla, P., Borraccino, A., De Marinis, L., Pivonello, R., Grottoli, S., Losa, M., Cannavò, S., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0084 · Cited by 219
Self-citation
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Andela, C. D., Scharloo, M., Pereira, A. M., Kaptein, A. A., & Biermasz, N. R. (2015) · Pituitary · doi:10.1007/s11102-015-0636-7 · Cited by 142
Diabetes in Patients With Acromegaly
Hannon, A. M., Thompson, C. J., & Sherlock, M. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0838-7 · Cited by 111
Primary Empty Sella Syndrome and the Prevalence of Hormonal Dysregulation
Auer, M. K., Stieg, M. R., Crispin, A., Sievers, C., Stalla, G. K., & Kopczak, A. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0099 · Cited by 99
“On the other hand, treating hormonal dysregulation has a positive effect on morbidity and quality of life (3, 4).”
BackgroundPredictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
Geraedts, V. J., Andela, C. D., Stalla, G. K., Pereira, A. M., van Furth, W. R., Sievers, C., & Biermasz, N. R. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00040 · Cited by 96
Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks
Díez, J. J., Sangiao-Alvarellos, S., & Cordido, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030893 · Cited by 81
“This particular group of patients exhibits a significant deterioration of health-related QoL that is improved by GH replacement [29].”
BackgroundImpact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]
Giovannini, L., Tirabassi, G., Muscogiuri, G., Somma, C. D., Colao, A., & Balercia, G. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0337 · Cited by 64
Andela, C. D., Lobatto, D. J., Pereira, A. M., van Furth, W. R., & Biermasz, N. R. (2018) · Pituitary · doi:10.1007/s11102-017-0860-4 · Cited by 45
Health-Related Quality of Life in Pituitary Diseases
Crespo, I., Valassi, E., Vives, A. S., & Webb, S. M. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.013 · Cited by 37
Growth hormone deficiency in treated acromegaly
Mazziotti, G., Marzullo, P., Doga, M., Aimaretti, G., & Giustina, A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.10.005 · Cited by 33
Tritos, N. A., Johannsson, G., Korbonits, M., Miller, K. K., Feldt-Rasmussen, U., Yuen, K. C. J., King, D., Mattsson, A. F., Jonsson, P. J., Koltowska-Haggstrom, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1013 · Cited by 31
The chronic syndromes after previous treatment of pituitary tumours
Romijn, J. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.84 · Cited by 28
Growth hormone deficiency in treated acromegaly and active Cushing's syndrome
Formenti, A. M., Maffezzoni, F., Doga, M., Mazziotti, G., & Giustina, A. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.03.002 · Cited by 26
Clinical predictors of GH deficiency in surgically cured acromegalic patients
Ku, C. R., Hong, J. W., Kim, E. H., Kim, S. H., & Lee, E. J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0304 · Cited by 24
Bonert, V. S., & Melmed, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00004-0 · Cited by 21
Improving Quality of Life in Patients with Pituitary Tumours
Crespo, I., Vives, A. S., Resmini, E., Valassix, E., Martínez-Momblán, M.-A., & Webb, S. M. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.01.32 · Cited by 13
van Bunderen, C. C., van Varsseveld, N. C., Heymans, M. W., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0515 · Cited by 14
Verrua, E., Ferrante, E., Filopanti, M., Malchiodi, E., Sala, E., Giavoli, C., Arosio, M., Lania, A. G., Ronchi, C. L., Mantovani, G., et al. (2014) · International Journal of Endocrinology · doi:10.1155/2014/581594 · Cited by 9
“It is at present difficult to ascertain whether this decline in GH levels might represent a sign of normalization of GH secretion pattern or, instead, of GH deficiency that frequently occurs in cured acromegalic patients [13, 14].”
BackgroundSelf-citationGrowth hormone replacement in adults with cured acromegaly: Efficacy and safety
Tritos, N. A. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101790 · Cited by 6
Beneficios y riesgos de la hormona del crecimiento en adultos con déficit de la misma
Díez, J. J., & Cordido, F. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2013.11.026 · Cited by 7
Fazeli, P. K., Teoh, J. G., Lam, E. L., Gerweck, A. V., Wexler, T., Teo, E. P., Russell, B. M., Durst, R. Y., McCarty, D., Weiner, R. B., et al. (2015) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2015.12.003 · Cited by 5
“Longer-term studies involving treatment of acroGHD patients with GH for up to 3 years also demonstrate sustained improvements in quality of life and cardiovascular risk markers [21, 51].”
BackgroundBelceanu, A. D., Bilhă, Ş., Leuștean, L., Ungureanu, M.-C., & Preda, C. (2024) · Endokrynologia Polska · doi:10.5603/ep.98923 · Cited by 4
Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test
Bioletto, F., Prencipe, N., Berton, A. M., Bona, C., Varaldo, E., Gasco, V., Ghigo, E., & Grottoli, S. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01731-0 · Cited by 1
Abdulhadi, B., Farmer, C. C., & Vaughan, T. B. (2022) · Contemporary Endocrinology · doi:10.1007/978-3-031-16258-9_11
Metadata
- Authors
- Giavoli, C., Profka, E., Verrua, E., Ronchi, C. L., Ferrante, E., Bergamaschi, S., Sala, E., Malchiodi, E., Lania, A. G., Arosio, M., Ambrosi, B., Spada, A., & Beck-Peccoz, P.
- Affiliations
- University of Milan (IT)
- Universitätsklinikum Würzburg (DE)
- Department of Clinical Sciences and Community Health (C.G., E.P., E.V., E.F., S.B., E.S., E.M., M.A., A.S., P.B.-P.), University of Milan,
- Corresponding author
- Giavoli, Claudia
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-11-01
- Volume
- 97
- Issue
- 11
- Pages
- 3983-3988
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2103849796
- Semantic Scholar
- f46ac07a1ce3daaaae24563b2d5c4d4f20a30af6
- Cited by
- 25
- References
- 22
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 7
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- growth hormone replacement therapy, acromegaly, growth hormone deficiency, recombinant human growth hormone, quality of life, insulin-like growth factor I, lipid profile, glucose tolerance, insulin resistance, body composition, hypopituitarism, non-functioning pituitary adenoma
- MeSH terms
- Acromegaly, Adult, Blood Glucose, Female, Humans, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Prospective Studies, Quality of Life, Recombinant Proteins, Treatment Outcome, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.